Granules India Ltd

Sanjay Kumar transfer and CSO resignation

• Sanjay Kumar moves Granules India CSO to CEO of Ascelis Peptides Pvt Ltd, effective 13 August 2026.
• Resignation as Chief Strategy Officer effective 13 August 2026 due to internal transfer to subsidiary.

AGM Details

• AGM held 06 Aug 2026 at 11:30 IST via video conferencing.
• Cut-off date for voting: 30 Jul 2026.
• Attendance: 67 members via VC.
• Quorum and proceedings chaired by Chairman & MD.

Key Resolutions and Outcomes

• Adopt standalone and consolidated financial statements for FY2025-26; ordinary; passed.
• Declare final dividend of Rs 1.75 per equity share; ordinary; approved.
• Re-appoint Priyanka Chigurupati (retire by rotation); ordinary; passed with near-unanimous support.
• Auditors for FY2025-26 appointed; ordinary; reaffirmed.

Director Changes

• Priyanka Chigurupati re-appointed as director.

Auditor Appointments

• Statutory Auditors: Dhanunjaya & Haranath Chartered Accountants, Hyderabad, reappointed for FY2025-26.

Meeting Details

• Date: July 21, 2026; virtual group earnings conference call; time not disclosed.
• Event: Q1 FY27 Earnings Conference Call organized by Granules India.

Participants

• Chairman and Managing Director; Executive Director; Chief Financial Officer; Chief Technology Officer; Chief Strategy Officer attended.
• Moderator: MUFG Investor Relations.

Purpose

• Earnings results discussion for Q1 FY27.
• Update on strategic initiatives and peptide CDMO progress.

Availability

• Transcript and investor presentation available on Granules India website.
• Conference recording of the call is available.

Event overview

• Transcript of Q1 FY27 earnings call released and uploaded.
• Key topics include revenue, margins, EBITDA, PAT, and cash flow.

Financial highlights

• Q1 FY27 revenue INR 1,477 crore, up 22% YoY.
• Gross margin 65.6%; EBITDA INR 339 crore; PAT INR 180 crore.
• ROCE 18%; net debt to EBITDA 0.07x; net debt INR 1,012 crore.
• Operating cash flow INR 387 crore; Q1 capex INR 89 crore; full-year capex guidance INR 600 crore.

Regulatory and operational updates

• Genome Valley investment completed; capacity up about 40%.
• FDA remediation progress: 7 of 8 facilities with clean EIR; FDA review ongoing.
• GLS capacity utilization: GLS low; GPI at about 70% with expansion planned.
• Pending approvals: ~18 total; 9 facility approvals; 9-13 oncology products in development.

Overview

• Standalone BRSR for FY2025-26; core activity pharmaceuticals API, PFI, and finished dosages.
• Exports account for about 92% of turnover; six plants and four R&D centers in India.
• Assurance: Bureau Veritas; BRSR Core – reasonable; remaining parts under limited assurance.
• Reporting boundary is standalone for Granules India Limited.

Key ESG Risks & Opportunities

• Climate change and GHG emissions: transition risks and net-zero opportunities via energy efficiency.
• Water management: Zero Liquid Discharge, wastewater recycling, and 2032 water neutrality goal.
• Waste management: high waste diversion; ZWTL Platinum; EPR registration and co-processing.
• Employee engagement and well-being: wellness programs, health insurance, annual health checks.
• Occupational health and safety: ISO 45001; zero reportable incidents; safety governance.
• Data privacy and cybersecurity: risk; ISO 27001 planned.
• Human capital development: training and retention; Swarna Bharat Trust partnerships.

Governance & Policy Highlights

• Board-level Sustainability & CSR Committee convenes semi-annually for ESG oversight.
• Policies include COBC, anti-bribery, whistleblower, POSH; board-approved.
• ISO 45001 and ISO 14001; SA8000 compliance across sites.
• Assurance: Bureau Veritas BRSR Core reasonable; remaining parts limited assurance.
• No penalties or fines reported in FY2025-26.
• UNGC member; UN-WEP signatory; PSCI supplier partner; BSC and NSCI members.
• Sedex Supplier Plus certification achieved; Haleon Sustainability Award 2026.
• Founding member of C4IR-WEF; public policy advocacy framework under development.

Social Responsibility & Workforce

• Permanent employees: 4,306; 3,842 male, 464 female; total workers: 2,217; 1,760 male, 457 female.
• Board female representation: 27%; KMP female: 50%.
• LTIFR zero; no fatalities; 100% safety training and 100% health screenings.
• All employees' wages above minimum; workers: 98% at minimum, 2% above.
• CSR beneficiaries include 3,677 breast health consultations; 1,769 mammograms; 395 ultrasounds.
• Pharma Pathshala trained 1,600+ students; 150+ current-year participants; Vidya Volunteers support 600+ students.
• 178 men took paternity leave; 23 left; 14 women took maternity; all returned to work.

Environmental Performance

• Total energy 990 TJ; renewables 366 TJ; renewables share 37%; electricity from renewables 98%.
• Scope 1 emissions 59,851 tCO2e; Scope 2 1,285 tCO2e; total 61,136 tCO2e; intensity 1.76.
• Total water withdrawal 398,308 KL; consumption 239,951 KL; 39% recycled.
• Total waste 8,537.5 MT; 83% hazardous waste co-processing; 100% non-hazardous recycled.
• Gagillapur ZWTL Platinum+ with 99% waste diversion; ISO 14001 across all plants.
• Energy savings: 2,309,552 kWh; GHG reduction 1,640 tCO2e; RECs offset 56,800 tCO2e.
• Net Zero by 2050 with SBTi validation; water neutrality initiatives and 18,000 native trees planted.

Stakeholder Engagement & Complaints

• Stakeholders engaged: investors, customers, suppliers, employees, workers, communities.
• Customer complaints: 630 filed; 0 pending at year-end.
• Employees/workers safety complaints: 27,701 filed; all resolved.
• POSH complaints: 2 filed; 0 upheld.
• Grievance mechanisms ensure timely resolution; no retaliation for whistleblowing.

Other Notable Metrics

• Sedex Supplier Plus certification achieved; 82% of suppliers completed ESG survey; 85% engaged.
• Supplier Sustainability Program covers over 85% of suppliers; 82% completed survey.
• 0 data breaches; 0 privacy incidents; product recalls: 2 voluntary recalls.
• Privacy policy; ISO 27001 certification planned by FY2027.
• Public policy affiliations: PSCI, UNGC, UN-WEP, C4IR; CII; BDMAI; FTAPCCI.

AGM Highlights

• 35th AGM on 6 August 2026 at 11:30 IST; mode: VC/OAVM.
• Register of Members closed 31 July to 6 August 2026.
• Final dividend proposed at ₹1.75 per equity share; payable by 04 September 2026.
• Adopt standalone financial statements for year ended 31 March 2026.
• Adopt consolidated financial statements for year ended 31 March 2026.
• Re-appoint Priyanka Chigurupati as Executive Director, liable to retire by rotation.
• Dr. Kandiraju Venkata Sitaram Rao ceased as Joint MD & CEO with effect from 1 Aug 2025.
• Vinodkumar Parur appointed Chief Financial Officer/CHRO from 17 November 2025.
• Material Related Party Transactions: Senn Chemicals AG: Corporate guarantee ₹2,746.94m; Guarantee commission ₹1.60m.
• Statutory auditors: M/s S.R. Batliboi & Associates LLP.

Meeting Details

• Q1 FY27 Earnings Conference Call on 21 July 2026 at 5:00 PM IST.
• Mode: virtual group call; dial-in numbers provided.
• Organizer: Granules India Limited.

Participants

• Key company participants: Chairman & MD; Executive Director; CFO; CTO; Chief Strategy Officer.

Purpose

• Discuss Q1 FY27 financial performance and business updates.

Additional Notes

• No mention of recording, transcript, or presentation availability.

Meeting Details

• Board meeting on July 21, 2026 to consider unaudited Q1 results for the quarter ended June 30, 2026.

Key Agenda Items

• Consider and approve unaudited financial results for Q1 ended June 30, 2026.

Other Notes

• Insider Trading Window shall remain closed till July 23, 2026 in view of the Board Meeting.